New Blood Biomarker Clusterin Predicts Heart Remodeling After Heart Attack and Death in Heart Failure | Research

The takeaway

Plasma clusterin levels were elevated in patients with left ventricular remodeling after heart attack and predicted cardiovascular death in heart failure patients, with silencing experiments showing clusterin drives heart cell enlargement alongside ANP and BNP natriuretic peptide expression.

CLU predicted CV death at 3 years
Circulating clusterin levels were significantly higher in heart failure patients who died from cardiovascular causes compared to survivors over 3-year follow-up

What the researchers found

Proteomic analysis of 246 patients (REVE-2 study) identified increased plasma clusterin in patients with high left ventricular remodeling after first anterior MI. In rat MI models, cardiac clusterin expression increased and correlated with remodeling parameters.

Silencing clusterin in hypertrophied cardiomyocytes decreased cell size, ANP and BNP expression, and ERK1/2 activity — establishing a prohypertrophic role. Both precursor (p-CLU) and mature (m-CLU) forms were increased in failing human hearts. Circulating clusterin was significantly higher in heart failure patients who died from cardiovascular causes during 3-year follow-up (n=99) compared to survivors (n=99).

Why it matters

Despite advances in treatment, predicting which patients will develop harmful heart remodeling after a heart attack remains a major clinical challenge. BNP is already the standard biomarker, but adding clusterin could improve prediction. More importantly, the discovery that clusterin actively promotes heart cell enlargement (alongside ANP/BNP upregulation) identifies a potential therapeutic target — blocking clusterin might prevent the remodeling that leads to heart failure.

How the study worked

Multi-level translational study: (1) proteomic biomarker discovery in 246 MI patients (REVE-2 cohort), (2) clusterin expression analysis in rat MI models, (3) functional studies using siRNA silencing in hypertrophied rat neonatal cardiomyocytes, (4) confirmation in failing human heart tissue, and (5) prognostic validation comparing plasma clusterin in 99 heart failure patients who died vs. 99 survivors over 3 years.

What this study cannot tell us

The prognostic analysis used a matched case-control design (99 deaths vs. 99 survivors) rather than a full cohort analysis. Functional studies were performed in neonatal rat cardiomyocytes, which may not fully represent adult human cardiac biology. The precise mechanism by which clusterin promotes hypertrophy via ERK1/2 needs further elucidation. External validation in independent cohorts is needed before clinical implementation.

How to read the evidence

Strong translational study published in Circulation: Heart Failure, combining human biomarker discovery (246 patients), animal models, mechanistic cell studies, human tissue confirmation, and clinical prognostic validation (198 patients). The multi-level approach significantly strengthens the evidence.

When this study was published

Published in 2018, this study identified clusterin as a novel cardiac biomarker. Subsequent research has continued to explore its role in cardiac biology, and its potential clinical utility is still being evaluated.

The bigger picture

This study extends the biomarker landscape beyond established natriuretic peptides (ANP, BNP) by identifying clusterin as both a predictor and a driver of cardiac remodeling. The finding that clusterin silencing reduces both cell size and natriuretic peptide expression suggests it acts upstream in the hypertrophy cascade. Combined with existing biomarkers, clusterin could improve risk stratification and potentially serve as a therapeutic target to prevent heart failure progression.

Questions still open

Could therapeutic clusterin inhibition prevent or reverse left ventricular remodeling after myocardial infarction?
Does adding clusterin to existing biomarker panels (BNP, troponin) meaningfully improve heart failure risk prediction?
Is the prohypertrophic effect of clusterin mediated entirely through ERK1/2, or are additional signaling pathways involved?

Common questions

What is left ventricular remodeling and why is it dangerous?

After a heart attack, the damaged area of the heart can't pump properly. The remaining healthy muscle tries to compensate by stretching and thickening — a process called remodeling. While initially adaptive, this remodeling progressively weakens the heart over time, eventually leading to heart failure. Predicting which patients will experience severe remodeling helps doctors intervene earlier with life-saving treatments.

How does clusterin relate to the natriuretic peptides ANP and BNP?

ANP and BNP are peptide hormones released by stressed heart cells — they're the standard blood tests used to diagnose and monitor heart failure. This study found that clusterin appears to act upstream: when researchers silenced clusterin in enlarged heart cells, both the cell enlargement and the ANP/BNP production decreased. This suggests clusterin helps drive the cardiac stress response that causes heart cells to enlarge and produce these peptide hormones.

Read the original research

Expression and Implication of Clusterin in Left Ventricular Remodeling After Myocardial Infarction.

Circulation. Heart failure, 11(6), e004838

View on PubMed ↗Publisher’s paper ↗

Citation

Turkieh, Annie; Fertin, Marie; Bouvet, Marion; Mulder, Paul; Drobecq, Hervé; Lemesle, Gilles; Lamblin, Nicolas; de Groote, Pascal; Porouchani, Sina; Chwastyniak, Maggy; Beseme, Olivia; Amouyel, Philippe; Mouquet, Frédéric; Balligand, Jean-Luc; Richard, Vincent; Bauters, Christophe; Pinet, Florence. (2018). Expression and Implication of Clusterin in Left Ventricular Remodeling After Myocardial Infarction.. Circulation. Heart failure, 11(6), e004838. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004838